Search results
Showing 1 to 15 of 360 results for eq-5d
The EQ-5D is a short questionnaire used to understand how a person’s health affects their quality of life. It is used in health research and to help inform decisions about healthcare treatments.
Modular update to NICE manuals: EQ-5D-5L value set: nice general consultation
We are listening to your views on this NICE general. Comments close 27 May 2026.
Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (TA1134)
Evidence-based recommendations on dupilumab (Dupixent) for treating severe chronic rhinosinusitis with nasal polyps in adults.
Find out more about changes to NICE’s cost-effectiveness thresholds and the recent EQ-5D-5L public consultation.
Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures in adults.
Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause (TA1143)
Evidence-based recommendations on fezolinetant (Veoza) for treating moderate to severe vasomotor symptoms associated with menopause.
Show all sections
Our modular updates framework ensures flexibility and consistency in updating our manuals and helps prioritise important updates.
Have your say on NICE's adoption of the new EQ-5D-5L value set
We have launched a public consultation on the proposed adoption of the new EQ-5D-5L value set which will help us to make more accurate assessments of how treatments improve health-related quality of life.
Prucalopride for the treatment of chronic constipation in women (TA211)
Evidence-based recommendations on prucalopride (Resolor) for treating chronic constipation in women.
Science policy projects with NICE.
Topotecan for the treatment of relapsed small-cell lung cancer (TA184)
Evidence-based recommendations on topotecan for treating relapsed small-cell cancer in adults.
Tofacitinib for moderately to severely active ulcerative colitis (TA547)
Evidence-based recommendations on tofacitinib (Xeljanz) for previously treated moderately to severely active ulcerative colitis in adults.
Human growth hormone (somatropin) in adults with growth hormone deficiency (TA64)
Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth hormone deficiency in adults.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.
Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)
Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women.